PBYI vs AZN

For growth investors, AstraZeneca PLC (AZN) is the stronger pick with 8.

6% revenue growth year-over-year, versus -0. 9% for Puma Biotechnology, Inc. (PBYI). Puma Biotechnology, Inc. (PBYI) offers the better valuation at 12. 2x trailing P/E (29. 0x forward), making it the more compelling value choice. Analysts rate Puma Biotechnology, Inc. (PBYI) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Puma Biotechnology, Inc.

(PBYI) is the cheapest at 12. 2x versus AstraZeneca PLC at 28. 3x. On forward P/E, AstraZeneca PLC is actually cheaper at 17. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AstraZeneca PLC (AZN) delivered a total return of +87.

0%, compared to -23. 0% for Puma Biotechnology, Inc. (PBYI). Over 10 years, the gap is even starker: AZN returned +268. 6% versus PBYI's -70. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AstraZeneca PLC (AZN) is the lower-risk stock at 0.

67β versus Puma Biotechnology, Inc. 's 1. 11β — meaning PBYI is approximately 66% more volatile than AZN relative to the S&P 500. On balance sheet safety, Puma Biotechnology, Inc. (PBYI) carries a lower debt/equity ratio of 22% versus 61% for AstraZeneca PLC — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AstraZeneca PLC (AZN) is pulling ahead at 8.

6% versus -0. 9% for Puma Biotechnology, Inc. (PBYI). On earnings-per-share growth, the picture is similar: AstraZeneca PLC grew EPS 190. 7% year-over-year, compared to -1. 6% for Puma Biotechnology, Inc.. Over a 3-year CAGR, AZN leads at 9. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AstraZeneca PLC (AZN) is the more profitable company, earning 17.

5% net margin versus 13. 6% for Puma Biotechnology, Inc. — meaning it keeps 17. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AZN leads at 23. 4% versus 16. 3% for PBYI. At the gross margin level — before operating expenses — AZN leads at 81. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AstraZeneca PLC (AZN) trades at 17.

7x forward P/E versus 29. 0x for Puma Biotechnology, Inc. — 11. 3x cheaper on a one-year earnings basis.

In this comparison, AZN (1.

8% yield) pays a dividend. PBYI does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AstraZeneca PLC (AZN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

67), 1. 8% yield, +268. 6% 10Y return). Both have compounded well over 10 years (AZN: +268. 6%, PBYI: -70. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PBYI is a small-cap deep-value stock; AZN is a large-cap quality compounder stock. AZN pays a dividend while PBYI does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.